Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung‐Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al. · The Lancet · 2010
Cited by 7,293 works. doi:10.1016/s0140-6736(10)61121-x
Authors
- Yung‐Jue Bang
- Eric Van Cutsem
- Andrea Feyereislova
- Hyun Cheol Chung
- Lin Shen
- Akira Sawaki
- Florian Lordick
- Atsushi Ohtsu
- Yasushi Omuro
- Taroh Satoh
- Giuseppe Aprile
- Julie Hill
- Michaela Lehle
- Josef Rüschoff
- Yoon‐Koo Kang
References
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
- Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World
- USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group